You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 7, 2024

FERAHEME Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Feraheme patents expire, and what generic alternatives are available?

Feraheme is a drug marketed by Covis and is included in one NDA.

The generic ingredient in FERAHEME is ferumoxytol. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the ferumoxytol profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Feraheme

A generic version of FERAHEME was approved as ferumoxytol by SANDOZ on January 15th, 2021.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for FERAHEME?
  • What are the global sales for FERAHEME?
  • What is Average Wholesale Price for FERAHEME?
Drug patent expirations by year for FERAHEME
Drug Prices for FERAHEME

See drug prices for FERAHEME

Recent Clinical Trials for FERAHEME

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Christopher J Chermansky, MDEarly Phase 1
National Institutes of Health (NIH)Early Phase 1
Lipella Pharmaceuticals, Inc.Early Phase 1

See all FERAHEME clinical trials

Pharmacology for FERAHEME
Paragraph IV (Patent) Challenges for FERAHEME
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
FERAHEME Injection ferumoxytol 30 mg/mL, 17 mL single-use vials 022180 1 2015-12-04

US Patents and Regulatory Information for FERAHEME

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Covis FERAHEME ferumoxytol SOLUTION;INTRAVENOUS 022180-001 Jun 30, 2009 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for FERAHEME

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Covis FERAHEME ferumoxytol SOLUTION;INTRAVENOUS 022180-001 Jun 30, 2009 ⤷  Sign Up ⤷  Sign Up
Covis FERAHEME ferumoxytol SOLUTION;INTRAVENOUS 022180-001 Jun 30, 2009 ⤷  Sign Up ⤷  Sign Up
Covis FERAHEME ferumoxytol SOLUTION;INTRAVENOUS 022180-001 Jun 30, 2009 ⤷  Sign Up ⤷  Sign Up
Covis FERAHEME ferumoxytol SOLUTION;INTRAVENOUS 022180-001 Jun 30, 2009 ⤷  Sign Up ⤷  Sign Up
Covis FERAHEME ferumoxytol SOLUTION;INTRAVENOUS 022180-001 Jun 30, 2009 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for FERAHEME

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Takeda Pharma A/S Rienso ferumoxytol EMEA/H/C/002215
Rienso is indicated for the intravenous treatment of iron-deficiency anaemia in adult patients with chronic kidney disease (CKD).The diagnosis of iron deficiency must be based on appropriate laboratory tests (see section 4.2).
Withdrawn no no no 2012-06-15
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for FERAHEME

See the table below for patents covering FERAHEME around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 1522318 ⤷  Sign Up
Germany 60043188 ⤷  Sign Up
Spain 2334555 ⤷  Sign Up
Portugal 1169062 ⤷  Sign Up
European Patent Office 1169062 OXYDES DE FER COLLOIDAUX THERMOSTABLES RECOUVERTS DE CARBOHYDRATES REDUITS ET DES DERIVES DE CARBOHYDRATES (HEAT STABLE COATED COLLOIDAL IRON OXIDES) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for FERAHEME

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1169062 2012C/052 Belgium ⤷  Sign Up PRODUCT NAME: FERUMOXYTOL; AUTHORISATION NUMBER AND DATE: EU/1/12/774/001 20120620
1169062 92114 Luxembourg ⤷  Sign Up PRODUCT NAME: FERUMOXYTOL
1169062 1290043-7 Sweden ⤷  Sign Up PRODUCT NAME: FERUMOXYTOL; REG. NO/DATE: EU/1/12/774/001 20120615
1169062 CA 2012 00050 Denmark ⤷  Sign Up
1169062 300558 Netherlands ⤷  Sign Up PRODUCT NAME: FERUMOXYTOL IN IEDERE DOOR HET BASISOCTROOI BESCHERMDE VORM; REGISTRATION NO/DATE: EU/1/12/774/001-002 20120615
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.